C2 CryoBalloon™ 180 Ablation System Dose De-escalation Study.

Status Enrolling by invitation

Clinical Trial Summary

The primary objective is to determine the safety, performance and efficacy of the C2 CryoBalloon 180 Ablation System ("CryoBalloon 180") used at decreasing doses in treatment naïve patients with low- or high-grade dysplastic Barrett's Esophagus (BE) or with residual BE after resection of dysplasia or early adenocarcinoma.

Clinical Trial Description

The procedure will be performed on an outpatient basis, and the CryoBalloon 180 Ablation system will be used for all ablations following the instructions for use provided with the product. Patients who meet the eligibility criteria will be assigned to one of the treatment groups and doses, depending on the order of their enrollment: In phase I, the first 25 patients will be treated with Dose 1 (lowest), in one application to ablate 50% of the esophageal circumference. All patients will undergo 10 week (±2 weeks) follow-up EGD to evaluate efficacy of the dose before the study continues. If follow-up shows that Dose 1 eradicates ≤60% of the treated BE (by median percentage) and no SAE's are reported, the treatment phase will continue but at the next incremental higer dose (Second Dose) after approval from the IRB. If the Dose 1 median BE surface regression percentage is ≥60%, the dose is defined as the therapeutic dose. In that case, an additional group of 25 patients will be enrolled at this dose, pending IRB approval. --------------------------------------------------------------- Dose-related SAEs include pain in the treatment area greater than 6 (0-10 VAS score) at 24 hours AND seven (7) days post-treatment; symptomatic stricture requiring an additional EGD with endoscopic dilation before the first follow-up EGD; symptomatic stricture at follow-up EGD; or any stricture (symptomatic or asymptomatic) preventing passage of the therapeutic endoscope at follow-up EGD. Any other serious adverse events within 30 days after treatment will also be evaluated by the Data and Safety Monitoring Board (DSMB) for relationship to the dose and severity. When a Dose-related serious adverse event occurs, the Holding Rule will be invoked and enrollment at that dose will be held until the DSMB has evaluated the event. ;

Study Design

Related Conditions & MeSH terms

Barrett Esophagus

Clinical Trial Details

NCT number	NCT03311451
Study type	Interventional
Source	Pentax Medical
Contact
Status	Enrolling by invitation
Phase	N/A
Start date	January 16, 2023
Completion date	December 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03554356` - Nitrous Oxide For Endoscopic Ablation of Refractory Barrett's Esophagus (NO FEAR-BE)	N/A
Completed	`NCT03015389` - Wide Area Transepithelial Sample Esophageal Biopsy Combined With Computer Assisted 3-Dimensional Tissue Analysis (WATS3D) For the Detection of High Grade Esophageal Dysplasia and Adenocarcinoma
Completed	`NCT03434834` - OCT Pilot in Esophagus	N/A
Terminated	`NCT04642690` - Nitrates and IL-8 in Barrett's Esophagus
Completed	`NCT03468634` - Raman Probe for In-vivo Diagnostics (During Oesophageal) Endoscopy	N/A
Recruiting	`NCT02310230` - An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy	N/A
Completed	`NCT00217087` - Endoscopic Therapy of Early Cancer in Barretts Esophagus	Phase 2
Completed	`NCT02284802` - Early Detection of Tumors of the Digestive Tract by Confocal Endomicroscopy	N/A
Recruiting	`NCT05530343` - Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance	N/A
Active, not recruiting	`NCT04151524` - Classification of Adenocarcinoma of the Esophagogastric Junction
Completed	`NCT00955019` - Novel Method of Surveillance in Barrett's Esophagus	Phase 2
Terminated	`NCT00386594` - Pilot Study of Oral 852A for Elimination of High-Grade Dysplasia in Barrett's Esophagus	N/A
Completed	`NCT00576498` - Novel Imaging Techniques in Barrett's Esophagus	N/A
Completed	`NCT02688114` - Healing of the Esophageal Mucosa After RFA of Barrett's Esophagus	N/A
Recruiting	`NCT06071845` - Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples	N/A
Completed	`NCT02560623` - A Minimally-Invasive Sponge on a String Device for Screening for Barrett's Esophagus	N/A
Recruiting	`NCT05056051` - Wide-Area Transepithelial Sampling in Endoscopic Eradication Therapy for Barrett's Esophagus	N/A
Recruiting	`NCT04001478` - Non-invasive Testing for Early oEesophageal Cancer and Dysplasia
Completed	`NCT03859557` - The Evaluation of Patients With Esophageal and Foregut Disorders With WATS (Wide Area Transepithelial Sample With 3-Dimensional Computer-Assisted Analysis) vs. 4-Quadrant Forceps Biopsy
Completed	`NCT04587310` - Does Laparoscopic Sleeve Gastrectomy Lead to Barrett's Esophagus, 5-year Esophagogastroduodenoscopy Findings: A Retrospective Cohort Study

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.